Establishment of the Dutch Nationwide, Interdisciplinary Infrastructure and Biobank for Fundamental and Translational Ovarian Cancer Research: Archipelago of Ovarian Cancer Research.

Autor:	Zelisse HS; Department of Pathology, Cancer Center Amsterdam, Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands, h.s.zelisse@amsterdamumc.nl., van Gent MDJM; Department of Gynaecologic Oncology, Centre for Gynaecologic Oncology Amsterdam, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., de Ridder S; Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., van der Aa MA; Department of Research and Development, IKNL - Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands., van Altena AM; Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands., Bart J; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Belien JAM; Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Boere IA; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Bosch SL; Department of Pathology, Laboratory for Pathology and Medical Microbiology (Stichting PAMM), Eindhoven, The Netherlands., Broeks A; Department of CFMPB (Core Facility - Molecular Pathology and Biobanking), the Netherlands Cancer Institute, Amsterdam, The Netherlands., Bulten J; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands., Collée M; Department of Clinical Genetics, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Groenendijk FH; Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Horlings HM; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Jansen MPHM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Jonges TGN; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., Kooreman LFS; Department of Pathology and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands., de Kroon CD; Department of Obstetrics and Gynaecology, Leiden University Medical Center, Leiden, The Netherlands., Lambrechts S; Department of Obstetrics and Gynaecology, Maastricht University Medical Centre, Maastricht, The Netherlands., Lok CAR; Department of Gynaecological Oncology, Centre for Gynaecologic Oncology Amsterdam, Antoni van Leeuwenhoek - the Netherlands Cancer Institute, Amsterdam, The Netherlands., Piek JM; Department of Obstetrics and Gynaecology, Catharina Hospital, Catharina Cancer Institute, Eindhoven, The Netherlands., Reyners AKL; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Roes EM; Department of Gynecologic Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Simons M; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands., Wisman GBA; Department of Gynaecologic Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Yigit R; Department of Obstetrics and Gynaecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Zweemer RP; Department of Gynaecological Oncology, Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Mom CH; Department of Gynaecologic Oncology, Centre for Gynaecologic Oncology Amsterdam, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., van de Vijver MJ; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Dijk F; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Jazyk:	angličtina
Zdroj:	Gynecologic and obstetric investigation [Gynecol Obstet Invest] 2022; Vol. 87 (6), pp. 389-397. Date of Electronic Publication: 2022 Nov 30.
DOI:	10.1159/000528330
Abstrakt:	Objectives: Ovarian cancer has the worst overall survival rate of all gynecologic malignancies. For the majority of patients, the 5-year overall survival rate of less than 50% has hardly improved over the last decades. To improve the outcome of patients with all subtypes of ovarian cancer, large-scale fundamental and translational research is needed. To accommodate these types of ovarian cancer research, we have established a Dutch nationwide, interdisciplinary infrastructure and biobank: the Archipelago of Ovarian Cancer Research (AOCR). The AOCR will facilitate fundamental and translational ovarian cancer research and enhance interdisciplinary, national, and international collaboration. Design: The AOCR biobank is a prospective ovarian cancer biobank in which biomaterials are collected, processed, and stored in a uniform matter for future (genetic) scientific research. All 19 Dutch hospitals in which ovarian cancer surgery is performed participate and collaborate in the AOCR biobank. Participants/materials, Setting, Methods: Patients of 16 years and older with suspected or diagnosed ovarian, fallopian tube, or primary peritoneal cancer are recruited for participation. Patients who agree to participate give written informed consent for collection, storage, and issue of their biomaterials for future studies. After inclusion, different blood samples are taken at various predefined time points both before and during treatment. In case of a diagnostic paracentesis or biopsy, the residual biomaterials of these procedures are stored in the biobank. During surgery, primary tumor tissue and, if applicable, tissue from metastatic sites are collected and stored. From each patient, a representative histological hematoxylin and eosin stained slide is digitalized for research purposes, including reassessment by a panel of gynecologic pathologists. Clinical and pathological data are obtained on a per-study basis from Dutch registries. Research proposals for the issue of biomaterials and data are evaluated by both the Archipelago Scientific Committee and the Steering Committee. Researchers using the biomaterials from the AOCR biobank are encouraged to enrich the biobank with data and materials resulting from their analyses and experiments. Limitations: The implementation and first 4 years of collection are financed by an infrastructural grant from the Dutch Cancer Society. Therefore, the main limitation is that the costs for sustaining the biobank after the funding period will have to be covered. This coverage will come from incorporation of budget for biobanking in future grant applications and from fees from external researchers and commercial parties using the biomaterials stored in the AOCR biobank. Moreover, we will apply for grants aimed at sustaining and improving research infrastructures and biobanks. Conclusions: With the establishment of the Dutch nationwide, interdisciplinary Archipelago of Ovarian Cancer Research infrastructure and biobank, fundamental and translational research on ovarian cancer can be greatly improved. The ultimate aim of this infrastructure is that it will lead to improved diagnostics, treatment, and survival of patients with ovarian cancer. (© 2022 The Author(s). Published by S. Karger AG, Basel.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu